Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-061 in advanced tumors
NCT04737122Phase 1Terminated
- Sponsor
- LaNova Medicines
- Start
- May 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of LM-061 in cancer (2 arms), sponsored by LaNova Medicines. Primary endpoints: Number of participants with adverse events and serious adverse events at 1 year, Dose-limiting toxicities at 28 days and 3 more. Started May 2021; status: terminated.
02
Drugs
LM-061
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04737122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04737122.